PT Sanbe Farma

Sanbe Farma was founded in 1975. As of now after more than three decades since inception, we are the largest pharmaceutical manufacturers in Indonesia and according the recent IMS Report, we rank highest among all the Pharmaceutical Manufacturers in Indonesia including Multinational Companies. Out of top 10 products ethically prescribed, 4 products are from Sanbe. Our market coverage in Indonesia includes more than 37,000 Doctors served by 1,000 Medical Representatives, through our associate's net-work of 1,100 Sales persons, 35 depots, 60 sub-depots and our corporate work force consisting 8,000 personnel. Our eight manufacturing facilities in Indonesia are cGMP approved plants as per the International Standards. Our sterile preparations unit (LVPs & SVPs) is the first in South East Asia with State-of-the-Art manufacturing equipment and technology from US and Europe and PIC(S) & TGA, Australia compliant.

Our international operations in 20 countries are set to make substantial contribution to the global healthcare. Our international operations cover not only export of our formulations to various developing and under developed countries, but also seek partnerships and alliances from and to developed and regulated markets such as North America and Europe with an aim to put Sanbe Farma on the global map to supply Generic and specialty formulations not only for Indonesia but also to the rest of the world. We are also looking for new acquisitions in potential markets to make our products globally available at affordable prices.

Our propinquity to invest in profitable and strategic ventures would encourage potential and strategic companies to partner with us for mutual benefit not only for generic formulations but also for New Drug Delivery Systems (NDDs), New Chemical Entities (NCEs) and Biosimilar products.

We are committed to strive for continued achievement to provide quality products for quality health through our sincere endeavor to become global generic pharmaceutical manufacturer from Indonesia in the days to come.